In these studies, using an experimental autoimmune encephalomyelitis model, 2-BFI administration reduced the expression of inflammatory cytokines, including interferon-g (IFN-γ), tumor necrosis factor-α (TNF-α) and microglial activation. The gene discussed is TNF; the disease is experimental autoimmune encephalomyelitis.